Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
TRF Pharma, Inc |
---|---|
Information provided by: | TRF Pharma, Inc |
ClinicalTrials.gov Identifier: | NCT00773890 |
This study is designed to assess the safety, tolerability, and activity of TRF-1101 on microvascular blood flow, vascular endothelial injury, and vasoocclusive pain associated with sickle cell disease.
Condition | Intervention | Phase |
---|---|---|
Sickle Cell Disease |
Drug: TRF-1101 Drug: Placebo |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Activity of TRF-1101 on Microvascular Blood Flow, Vascular Endothelial Injury, and Vasoocclusive Pain in Patients With Sickle Cell Disease |
Estimated Enrollment: | 80 |
Study Start Date: | July 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
TRF-1101: Experimental
Daily treatment with TRF-1101
|
Drug: TRF-1101
once daily treatment with 300 mg orally for 12 weeks
|
Placebo: Placebo Comparator
Daily treatment with placebo
|
Drug: Placebo
Daily treatment with TRF-1101 vehicle for 12 weeks
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Edward P Monaghan, PhD | 949-713-6024 | ed.monaghan@soarpharma.com |
United States, District of Columbia | |
Howard University | Recruiting |
Washington, District of Columbia, United States, 20060 | |
Contact: Ross Heffer 202-865-8287 rheffer@howard.edu | |
Principal Investigator: Victor Gordeuk, M.D. | |
United States, Georgia | |
Medical College of Georgia | Recruiting |
Augusta, Georgia, United States, 30912 | |
Contact: Leigh Wells, MSN 706-721-2171 lwells@mcg.edu | |
Principal Investigator: Abjullah Kutlar, M.D. | |
United States, Illinois | |
University of Illinios Medical Center | Recruiting |
Chicago, Illinois, United States, 60612 | |
Contact: Lani Krauz 312-413-0242 lignacio@uic.edu | |
Principal Investigator: Robert Molokie, M.D. | |
United States, Massachusetts | |
Boston Medical Center | Recruiting |
Boston, Massachusetts, United States, 02118 | |
Contact: Asif Qureshi, M.D. 617-414-5729 asif.qureshi@bmc.org | |
Principal Investigator: Lillian McMahon, M.D. | |
United States, Michigan | |
Wayne State University Medical Center | Recruiting |
Detroit, Michigan, United States, 48201 | |
Contact: Ernestine Favors 313-576-9366 favorse@karmanos.org | |
Principal Investigator: Paul Swerdlow, M.D. | |
United States, North Carolina | |
University of North Carolina | Recruiting |
Chapel Hill, North Carolina, United States, 27599 | |
Contact: Susan Jones 919-966-6876 skjones@med.unc.edu | |
Principal Investigator: Ken Ataga, M.D. |
Study Director: | Stephen H Embury, M.D. | TRF Pharma, Inc |
Responsible Party: | TRF Pharma, Inc. ( Edward Monaghan, Vice President, Clinical Operations ) |
Study ID Numbers: | 1101-201 |
Study First Received: | October 14, 2008 |
Last Updated: | October 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00773890 |
Health Authority: | United States: Food and Drug Administration |
Anemia, Hemolytic, Congenital Genetic Diseases, Inborn Hematologic Diseases Hemoglobinopathies Anemia |
Anemia, Hemolytic Pain Hemoglobinopathy Anemia, Sickle Cell Sickle cell anemia |